Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)

CNY 11.25

(2.18%)

Market Cap (In CNY)

4.55 Billion

Revenue (In CNY)

496.11 Million

Net Income (In CNY)

17.55 Million

Avg. Volume

1.21 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.06-16.1
PE
-
EPS
-
Beta Value
0.613
ISIN
CNE1000051H8
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Shaowen Fan
Employee Count
-
Website
https://www.olymvax.com
Ipo Date
2021-06-08
Details
Olymvax Biopharmaceuticals Inc. develops and supplies vaccines. The company offers vaccines for Tetanus, a deadly infectious disease that causes nervous system toxicity by toxigenic clostridium tetanus; and haemophilus influenzae type b. it also develops vaccines for Staphylococcus aureus, a pathogenic bacterium that causes hospital infection and community infection; and Group A streptococcus disease. The company was founded in 2009 and is based in Chengdu, China.